Bristol-Myers Squibb, a global biopharmaceutical company, has named Robert Bertolini, Matthew Emmens and Theodore Samuels as its directors, temporarily expanding its membership until the firm's annual meeting elections on 2 May, it is reported today.

Bertolini brings strategic and operational leadership experience from Bausch & Lomb, where he recently served as president and chief financial officer prior to the company's sale to Valeant. He also brings expertise from Schering-Plough, where he was executive vice president and chief financial officer, and more than 20 years of corporate finance experience from PricewaterhouseCoopers.

Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief executive and chairman at Shire, president of Merck KGaA's pharmaceutical division, and president and chief executive of AstraZeneca and Merck & Co's joint venture, Astra Merck.

Samuels also brings business and operational experience to the position, with a particular expertise in economics, capital markets and investment decision-making. He presently serves as a director at Perrigo Company and http://www.Stamps.com, and is the former president of Capital Guardian Trust Company, and global equity portfolio manager at Capital Group.